Research programme: glaucoma therapies - Alcon/Vernalis

Drug Profile

Research programme: glaucoma therapies - Alcon/Vernalis

Alternative Names: Glaucoma therapies research programme - Alcon/Vernalis

Latest Information Update: 17 Jan 2005

Price : $50

At a glance

  • Originator Alcon; Vernalis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 17 Sep 2004 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
  • 17 Sep 2004 Discontinued - Preclinical for Glaucoma in United Kingdom (unspecified route)
  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top